SCA Pharmaceuticals Issues Voluntary Nationwide Recall of Specific Products Due to Potential Contamination:

SCA Pharmaceuticals Issues Voluntary Nationwide Recall of Specific Products Due to Potential Contamination:

For Immediate Release

October 20, 2017

Contact

Consumers

SCA Pharmaceuticals
 877-550-5059

Media

Mr. Vamsi Vasireddy
SCA Pharmaceuticals
 877-550-5059

Announcement

SCA Pharmaceuticals LLC (“SCA Pharmaceuticals”) is voluntarily recalling all/the following lots of the below listed injectable products to the hospital level. The is a potential for the products to contain microbial contamination.

Administration of a drug product, intended to be sterile, that may contain microbial contamination has the potential to result in serious adverse events which may include life-threatening infections. SCA Pharmaceuticals has not received any customer complaints or reports of adverse events related to this issue, but out of an abundance of caution, is voluntarily initiating this recall.

Product Name Product Number Type of Packaging Indication SCA Lot Number Beyond Use Date Quantity Shipped Date(s) Distributed
Succinylcholine Chloride 20 mg/mL 10 mL syringe 70004-0910-
29
Rigid plastic syringe, 10mL Skeletal muscle relaxant 20170726@35 10/24/2017 1248 07/27/2017
– 07/28/2017
Hydromorphone 1 mg/mL in 25 mL 0.9% Sodium Chloride 70004-0303-
17
Rigid plastic syringe, 30mL Analgesic 20170808@52 11/06/2017 128 08/09/2017
Fentanyl 2 mcg/mL + Bupivacaine 0.125% in 250 mL 0.9% Sodium Chloride 70004-0231-
40
Flexible plastic IV bag, 250mL Analgesic 20170814@20 11/12/2017 116 08/16/2017
– 08/25/2017
Hydromorphone 20 mcg/mL + Bupivacaine 0.075% in 50 mL 0.9% Sodium Chloride 70004-0331-
22
Flexible plastic IV bag, 50mL Analgesic 20170816@65 10/30/2017 60 08/18/2017
Morphine 1 mg/mL in 50 mL 0.9% Sodium Chloride 70004-0100-
22
Flexible plastic IV bag, 50mL Analgesic 20170901@25 11/30/2017 238 09/06/2017
– 09/27/2017
Morphine 1 mg/mL in 100 mL 0.9% Sodium Chloride (CADD) 70004-0100-
63
Flexible plastic bag inside
rigid translucent plastic case (CADD), 100mL
Analgesic 20170905@24 12/04/2017 60 09/06/2017
– 09/18/2017
Oxytocin 30 units added to 500 mL Lactated Ringers 70004-0086-
44
Flexible plastic IV bag, 500mL Precipitate Labor 20170912@13 10/22/2017 450 09/13/2017
– 09/14/2017
Phenylephrine 100 mcg/mL 10 mL in 12 mL syringe 70004-0810-
12
Rigid plastic syringe, 12mL Hypotension 20170920@53 12/19/2017 1221 09/22/2017

 

Product Name Product Number Type of Packaging Indication SCA Lot Number Beyond Use Date Quantity Shipped Date(s) Distributed
Fentanyl 2 mcg/mL (as citrate) Ropivacaine HCl 0.1% 70004-0264-
64
Flexible plastic bag inside
rigid translucent plastic case (CADD), 100mL
Analgesic 20170815@26 11/13/2017 20 08/17/2017
Calcium Gluconate 2 g added to 50 mL 0.9% Sodium Chloride 70004-0510-
30
Flexible plastic IV bag, 50mL Hypocalcemia 20170920@20 11/09/2017 76 9/26/2017
Rocuronium 10 mg/mL 5 mL in 6 mL syringe 70004-850-
09
Rigid plastic syringe, 6mL Skeletal muscle relaxant 20171004@4 01/09/2018 487 10/05/2017

These injectable products’ indicated use and package type are identified in the above table. The affected product lots are also included in the table above. The product can be identified by the attached labels. The products associated with this recall were distributed nationwide to hospitals.

SCA Pharmaceuticals is notifying its customers via telephone, email and US mail and is arranging for return/replacement of all recalled products. Customers that have product which is being recalled, as indicated in the list above, should discontinue use immediately and return the product to SCA Pharmaceuticals at the address below.

SCA Pharmaceuticals
8821 Knoedl Court Little Rock, AR 72205

Consumers with questions regarding this recall can contact SCA Pharmaceuticals at 877-550-5059, between the hours of 8:00 am and 5:00 pm (Central Standard Time), Monday thru Friday.

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the Food and Drug Administration.

###

Page Last Updated: 10/20/2017 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s